Ionis Licenses Novel Antisense Drug for the Treatment of CNM to Dynacure
Ionis Pharmaceuticals and Dynacure announced that Dynacure has licensed IONIS-DNM2-2.5Rx (Dyn101), a Generation 2.5 antisense drug targeting dynamin 2 for the treatment of centronuclear…
Read More...
Read More...
